Connect Biopharma Holdings Ltd (CNTB) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN USG235491010

Price
0.68 USD
Market cap
42.65 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Connect Biopharma Holdings Ltd financials

Fiscal year2025
Revenue64,000.00 USD
Operating income-58.07 m USD
EBIT-55.28 m USD
Net income-55.48 m USD
Diluted EPS – continuing operations-1.00 USD

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Connect Biopharma Holdings Ltd

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.